Voyageur is a Canadian public company listed on the TSXV under the trading symbol VM. Voyageur is focused on the development of barium, iodine and carbon Active Pharmaceutical Ingredients (“API”) and high-performance cost-effective imaging contrast agents for the medical imaging marketplace. Voyageur’s goal is to initially generate positive cash flow from operations using third party GMP pharmaceutical manufacturers in Canada. Ultimately, Voyageur has plans to build all the required infrastructure to become 100% self-sufficient across all manufacturing activities. Voyageur owns a 100% interest in three barium sulphate (barite) projects including the Frances Creek property, suitable in grade for the pharmaceutical marketplace, with additional interests in a high-grade iodine, lithium & bromine brine project located in Utah, USA.
Voyageur Pharmaceuticals Ltd.
Critical Minerals Institute Official Member
Disclaimer: All stock information on InvestorIntel.com is currently being fed from multiple sources and is updated automatically every 10-minutes. The information on this site is for information purposes only and InvestorIntel Corp. is neither responsible nor liable for the accuracy of this data.
InvestorIntel Features on Voyageur Pharmaceuticals Ltd.
-
Offering freedom from China on Foreign Medical Imaging Supplies, Voyageur Pharmaceuticals announces another key milestone
Barium and iodine-based radiographic contrast media (RCM) are types of RCM used in diagnostic imaging. Both work by…
-
Voyageur’s quest to become the only fully integrated company in the radiographic contrast media field accelerates timeline with design of a carbon neutral pharmaceutical plant
Did you know that when you go to the doctor and require an X-Ray or scan in many…
-
Brent Willis of Voyageur Pharmaceuticals on securing a domestic medical imaging agent supply
In this InvestorIntel interview with host Tracy Weslosky, Voyageur Pharmaceuticals Ltd.’s (TSXV: VM) President and CEO Brent Willis,…
-
Voyageur Pharmaceuticals completes FDA submission milestone for first barium contrast product license application
Radiographic contrast media are substances used in diagnostic imaging tests such as ultrasound, X-rays, CT scans and MRI…
-
Brent Willis of Voyageur Pharmaceuticals discusses the high IRR and NPV in its recent PEA
In a recent InvestorIntel interview, Tracy Weslosky spoke with Brent Willis, President and CEO of Voyageur Pharmaceuticals Ltd. (TSXV:…
-
Voyageur Pharmaceuticals’ X-Ray Contrast Media Provides a Dramatic Increase in Valuation
Assuming you aren’t a meme stock or an equity driven by the Reddit army, then you know you’ve…
-
Voyageur Pharmaceuticals’ Brent Willis on creating the first vertically integrated medical radiological contrast media supplier in NA
In a recent InvestorIntel interview, Tracy Weslosky spoke with Brent Willis, President and CEO of Voyageur Pharmaceuticals Ltd. (TSXV:…